Pacific Biosciences of California (NASDAQ:PACB) Releases Earnings Results, Misses Estimates By $0.01 EPS

Pacific Biosciences of California (NASDAQ:PACB) posted its quarterly earnings results on Wednesday. The biotechnology company reported ($0.14) EPS for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.01), FiscalAI reports. Pacific Biosciences of California had a negative net margin of 80.35% and a negative return on equity of 571.06%.

Here are the key takeaways from Pacific Biosciences of California’s conference call:

• Leadership transition: Christian Henry stepped down as CEO and will remain on PacBio’s board as an advisor, with Mark Van Oene taking over immediately and prioritizing clinical-market expansion, SMRT Next adoption, and leaner execution.
• SMRT Next momentum is encouraging, with more than one-third of the installed base enabling the new software in June. PacBio expects the multi-use chemistry, which lowers the listed cost of a 20x HiFi genome by 30%, to drive higher throughput, larger population-scale projects, and improved utilization over time.
• Second-quarter revenue was $39 million, roughly flat year over year, while Vega placements declined to 26 from 38 amid academic and government funding constraints. PacBio lowered its 2026 revenue outlook to $155 million–$165 million and expects consumables pull-through of only $200,000–$225,000 per Revio system.
• Non-GAAP gross margin fell to 36% due to compute and memory costs, lower manufacturing volumes, and $1.1 million of Vega manufacturing-transition expenses. The company now expects 2026 gross margin of 35%–37% and cash-flow breakeven in 2028, a year later than previously anticipated, despite planned restructuring savings.
• Clinical adoption continues to strengthen, particularly in EMEA, where revenue grew 52% year over year and clinical consumables shipments rose 67% globally. Recent publications supporting HiFi sequencing for rare-disease diagnostics and other clinical applications could help accelerate payer and health-system adoption.

Pacific Biosciences of California Price Performance

NASDAQ:PACB traded down $0.15 during trading hours on Wednesday, hitting $1.29. The company’s stock had a trading volume of 11,563,018 shares, compared to its average volume of 6,571,097. Pacific Biosciences of California has a twelve month low of $1.09 and a twelve month high of $2.73. The stock has a fifty day simple moving average of $1.47 and a 200-day simple moving average of $1.57. The company has a market capitalization of $400.67 million, a P/E ratio of -3.00 and a beta of 2.31.

Pacific Biosciences of California News Summary

Here are the key news stories impacting Pacific Biosciences of California this week:

• Positive Sentiment: PacBio introduced faster runs, up to 50% more HiFi data and new compliance controls for its Vega sequencing system. The new chemistry is expected to produce up to 90 gigabases per run at 40% lower cost per gigabase, potentially improving customer economics and competitiveness. PacBio Announces Faster Runs, Up to 50% More HiFi Data, and New Compliance Controls for the Vega system
• Neutral Sentiment: Mark Van Oene was appointed president and chief executive officer, replacing Christian Henry after six years. The leadership change could bring a new strategic focus, but it also creates execution and transition risk while PacBio works to improve growth and profitability. PacBio Appoints Mark Van Oene as President and Chief Executive Officer
• Negative Sentiment: PacBio reported a second-quarter loss of $0.14 per share, compared with a $0.13 loss a year earlier. Results were described as roughly in line with the Zacks consensus but slightly below the broader consensus estimate of a $0.13 loss, while sales came in below analyst expectations. Pacific Biosciences of California Reports Q2 Loss, Lags Revenue Estimates
• Negative Sentiment: The company issued fiscal 2026 revenue guidance of $155 million to $165 million, below the $167.4 million analyst consensus. The outlook reinforces concerns about funding pressure, pricing challenges and the pace of adoption of PacBio’s sequencing platforms. PacBio Announces Second Quarter 2026 Financial Results

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Creative Planning grew its holdings in shares of Pacific Biosciences of California by 245.9% during the 2nd quarter. Creative Planning now owns 175,690 shares of the biotechnology company’s stock valued at $218,000 after purchasing an additional 124,893 shares during the last quarter. Cetera Investment Advisers lifted its stake in Pacific Biosciences of California by 10.1% in the 2nd quarter. Cetera Investment Advisers now owns 104,725 shares of the biotechnology company’s stock valued at $130,000 after purchasing an additional 9,617 shares during the last quarter. Prudential Financial Inc. lifted its stake in Pacific Biosciences of California by 73.0% in the 2nd quarter. Prudential Financial Inc. now owns 35,684 shares of the biotechnology company’s stock valued at $44,000 after purchasing an additional 15,062 shares during the last quarter. Invesco Ltd. boosted its position in Pacific Biosciences of California by 60.0% in the second quarter. Invesco Ltd. now owns 839,340 shares of the biotechnology company’s stock valued at $1,041,000 after buying an additional 314,697 shares in the last quarter. Finally, HUB Investment Partners LLC acquired a new stake in Pacific Biosciences of California in the second quarter valued at approximately $77,000.

Analyst Ratings Changes

Several equities analysts have commented on the stock. Barclays raised their target price on shares of Pacific Biosciences of California from $1.00 to $1.50 and gave the company an “underweight” rating in a report on Monday, May 11th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Pacific Biosciences of California in a report on Friday, July 17th. Finally, Zacks Research lowered shares of Pacific Biosciences of California from a “strong-buy” rating to a “hold” rating in a research report on Monday, April 20th. One investment analyst has rated the stock with a Buy rating, two have issued a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Reduce” and a consensus price target of $1.83.

About Pacific Biosciences of California

Pacific Biosciences of California, Inc develops, manufactures and sells high-performance DNA sequencing systems for genetic and genomic analysis. The company’s proprietary single-molecule, real-time (SMRT) sequencing technology is designed to enable long-read sequencing, offering high accuracy for applications such as de novo genome assembly, transcriptome characterization and structural variation analysis. Pacific Biosciences markets a suite of instruments, including the Sequel and Sequel IIe systems, alongside reagents, consumables and data analysis software to support a range of life science research.

Founded in 2004 and headquartered in Menlo Park, California, Pacific Biosciences has expanded its global reach by serving academic institutions, biotechnology and pharmaceutical companies, and government research centers across North America, Europe and Asia.